Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Company Deals Digital

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Fineline Cube Jul 21, 2026
Company Deals

Samsung Biologics Bids $1.8 Billion for PolyPeptide Group to Enter High-Growth Peptide Therapeutics Market

Fineline Cube Jul 21, 2026
Company Deals

Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients

Fineline Cube Jul 21, 2026
Company Deals

Hisun Pharmaceutical Secures Exclusive Rights to TISA-818 – Novel Multi-Target Immunomodulator for ARDS and Pulmonary Fibrosis

Fineline Cube Jul 21, 2026
Policy / Regulatory

China Launches 12th Batch of National Drug Procurement with Vonoprazan and Vitamin B6 Drawing Record Competition

Fineline Cube Jul 21, 2026
Company Drug

Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC

Fineline Cube Jul 22, 2026
Company Drug

Gilead and Merck to Present Phase 3 ISLEND Trial Data for Once-Weekly Oral HIV Regimen at AIDS 2026 Conference

Fineline Cube Jul 22, 2026
Company Deals

TJ Biopharma Secures Series C2 Funding to Accelerate Autoimmune and Oncology Pipeline

Fineline Cube Sep 30, 2025

China‑based TJ Biopharma announced today the successful completion of a Series C2 financing round that raised...

Company Deals

Full‑Life Technologies Raises $77 M in Series C and Debt Funding

Fineline Cube Sep 30, 2025

Full‑Life Technologies, a global radiotherapeutics integrator, announced today the successful completion of $77 million in financing,...

Company

GSK Names Luke Miels as CEO to Drive Growth

Fineline Cube Sep 30, 2025

GlaxoSmithKline (GSK; NYSE: GSK) announced that Luke Miels has been appointed CEO Designate and will...

Company Drug

Simnova Secures FDA IND for CAR‑NK Therapy in SLE

Fineline Cube Sep 30, 2025

Shanghai Simnova Biotech Co., Ltd. (Simnova) announced that its CD19‑targeted chimeric antigen receptor gene‑modified natural...

Company Drug

Sinopharm Secures NMPA Approval for QuadrivalentHPV Vaccine

Fineline Cube Sep 29, 2025

China’s Sinopharm Group Co., Ltd. (Chengdu Institute of Biological Products, a subsidiary of the China...

Company Drug

Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First‑In‑Class Glucokinase Activator

Fineline Cube Sep 29, 2025

China‑based Hua Medicine (HKG: 2552) announced that the Hong Kong Department of Health has accepted its...

Company Drug

Xinhua Pharma Wins China Trial Approval for Dual‑Mechanism PAH Drug LXH‑1211

Fineline Cube Sep 29, 2025

Shandong Xinhua Pharmaceutical Co., Ltd. (HKG: 0719) announced that its pulmonary arterial hypertension (PAH) candidate...

Company Drug

Simcere Secures FDA Approval for ADC SIM0609 in Advanced Solid Tumors

Fineline Cube Sep 29, 2025

Simcere Pharmaceutical Group Limited (HKG: 2096) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

CMS Wins NMPA Green Light for Phase‑3 Trial of MG‑K10 Anti‑IL‑4Rα in Chronic Urticaria

Fineline Cube Sep 29, 2025

China Medical System Holdings Limited (CMS, HKG: 0867) announced that the National Medical Products Administration...

Company Drug

Eisai & Biogen Secure Leqembi China Maintenance Approval

Fineline Cube Sep 29, 2025

Japanese drugmaker Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB) announced...

Company Drug

HanX Biopharmaceuticals Secures NMPA Approval for HX044‑HX008 PD‑1 Therapy Combination in Advanced Solid Tumors

Fineline Cube Sep 29, 2025

HanX Biopharmaceuticals (Wuhan) Co., Ltd., a fast‑growing Chinese biotech, announced that the National Medical Products...

Company Deals Drug

Novatim Partners with VRise to Launch KQ‑2003 CAR‑T in India

Fineline Cube Sep 29, 2025

Novatim Immune Therapeutics (Zhejiang) Co., Ltd., a leading Chinese cancer‑immunotherapy firm, announced an exclusive licensing...

Company Drug

CMS Announces Phase 3 Success of Ruxolitinib Cream in Atopic Dermatitis

Fineline Cube Sep 28, 2025

China Medical System Holdings Limited (CMS, HKG: 0867) reported that its Phase 3, randomized, double‑blind, placebo‑controlled...

Company

Merck Names Kai Beckmann as Incoming CEO, Signals Smooth Leadership Transition

Fineline Cube Sep 28, 2025

Merck KGaA (ETR: MRK) announced that Kai Beckmann will assume the roles of Chair of...

Policy / Regulatory

Trump’s New Pharmaceutical Tariffs Will Be Limited to 15% for EU and Japan, White House Says

Fineline Cube Sep 28, 2025

A White House spokesperson clarified that President Donald Trump’s proposed tariffs on imported pharmaceuticals will not...

Company Digital

Beijing Unicet’s QH104A Receives Chinese NMPA Approval for CNS Solid‑Tumor Clinical Trials

Fineline Cube Sep 28, 2025

Beijing Unicet Biotechnology Co., Ltd. announced that its pioneering QH104A—the world’s first B7H3‑targeted, off‑the‑shelf allogeneic...

Company Deals

Wolters Kluwer and the Chinese Academy of Medical Sciences Sign AI‑Driven Medical‑Information Collaboration

Fineline Cube Sep 28, 2025

Wolters Kluwer announced a preliminary collaboration agreement with the Institute of Medical Information of the...

Drug

Leo Pharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor

Fineline Cube Sep 28, 2025

Denmark-based dermatology specialist LEO Pharma A/S announced that the Greater Bay Area’s first prescription of...

Company Deals

Shanghai MicuRx and GenScript’s ProBio Unit Sign Strategic Deal to Accelerate Antibody‑Drug Conjugate (ADC) Development

Fineline Cube Sep 28, 2025

Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA: 688373) and Nanjing ProBio, a subsidiary of GenScript Biotech...

Policy / Regulatory

NHSA Launches 100‑Day Medical‑Insurance Fraud Crackdown Campaign

Fineline Cube Sep 26, 2025

The National Healthcare Security Administration (NHSA) announced a nationwide 100‑Day Action aimed at eradicating illegal...

Posts pagination

1 … 129 130 131 … 698

Recent updates

  • Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC
  • Gilead and Merck to Present Phase 3 ISLEND Trial Data for Once-Weekly Oral HIV Regimen at AIDS 2026 Conference
  • Alebund Pharmaceuticals Initiates Global Phase IIb Trial of AP306, First-in-Class Oral Pan-Phosphate Transporter Inhibitor for Hyperphosphatemia
  • Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline
  • Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC

Company Drug

Gilead and Merck to Present Phase 3 ISLEND Trial Data for Once-Weekly Oral HIV Regimen at AIDS 2026 Conference

Company Drug

Alebund Pharmaceuticals Initiates Global Phase IIb Trial of AP306, First-in-Class Oral Pan-Phosphate Transporter Inhibitor for Hyperphosphatemia

Others

Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.